Dongcheng Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
8 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
177Lu-LNC1010 / Dongcheng Pharma
NCT05410743: Evaluation of 177Lu-TATE-EB-01(LNC1010)in SSTR2-positive Tumors

Recruiting
1/2
30
RoW
177Lu-LNC1010 1, 177Lu-LNC1010 2, 177Lu-LNC1010 3, 177Lu-LNC1010 4
The First Affiliated Hospital of Xiamen University
SSTR2-positive Tumors
12/24
12/24
177Lu-LNC1003 / Dongcheng Pharma
NCT06237491: The Safety and Dosimetry Study of 177Lu-LNC1003 Injection

Not yet recruiting
1
12
NA
177Lu-LNC1003 Injection group 1, 177Lu-LNC1003 Injection group 2, 177Lu-LNC1003 Injection group 3
Yantai LNC Biotechnology Singapore PTE. LTD.
Metastatic Castration-resistant Prostate Cancer, mCRPC
11/25
12/25
NCT05613738: 177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer

Recruiting
N/A
9
RoW
1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01, 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01, 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01
Peking Union Medical College Hospital
Metastatic Castration-resistant Prostate Cancer
06/25
11/25
ChiCTR2200065809: An exploratory study of 177Lu-PSMA-EB-01 in patients with prostate specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer

Recruiting
N/A
30
 
Dose 60mCi 177Lu-PSMA-EB-01 ;Dose 100mCi 177Lu-PSMA-EB-01
The Affiliated Hospital of Southwest Medical University; The Affiliated Hospital of Southwest Medical University, Self-funded
prostate cancer
 
 
177Lu-LNC1004 / Dongcheng Pharma
INDIGO-FAPI, NCT06659705: Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis

Not yet recruiting
2
35
Europe
68Ga-FAPI for PET / CT scan and 177Lu-EB-FAPI for therapy
Institut Curie
Pancreatic Ductal Adenocarcinoma (PDAC)
01/29
01/30
NCT05400967: Diagnosis of Metastatic Tumors on 68Ga-FAPI PET-CT and Radioligand Therapy with 177Lu-EB-FAPI

Recruiting
1
10
RoW
68Ga-FAPI for PET / CT scan and 177Lu-EB-FAPI for therapy
Peking Union Medical College Hospital
177Lu-EB-FAPI
01/25
04/25
CISPD-5, NCT06081322: A Study to Evaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors

Recruiting
1
29
RoW
PRRT with 177Lu-EB-FAPI
Zhejiang University
Advanced Pancreatic Cancer and Cholangiocarcinoma
06/24
06/25
NCT05723640: The Safety and Dosimetry Study of 177Lu-LNC1004 Injection

Recruiting
1
24
RoW
177Lu-LNC1004 Injection group 1 radionuclide therapy, 177Lu-LNC1004 Injection group 2 radionuclide therapy, 177Lu-LNC1004 Injection group 3 radionuclide therapy, 177Lu-LNC1004 Injection group 4 radionuclide therapy
Yantai LNC Biotechnology Singapore PTE. LTD.
Solid Tumor, Unspecified, Adult
03/25
03/25

Download Options